Impact of Coronary Chronic Total Occlusion Revascularization Strategy on 30-Day Outcomes in Patients with Left

Yuchao Zhang1, Zheng Wu1, Shaoping Wang1

  • 1Center for Coronary Artery Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Diseases.

International Heart Journal
|November 13, 2024
PubMed

Insights

Coronary chronic total occlusion (CTO) revascularization in patients with left ventricular systolic dysfunction (LVSD) shows PCI is safer. CTO bypass grafting (CABG) increased major adverse cardiac or cerebrovascular events (MACCE) and myocardial infarction (MI) within 30 days.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Cardiac Surgery

Background:

  • Outcomes of revascularizing coronary chronic total occlusions (CTOs) in patients with left ventricular systolic dysfunction (LVSD) remain uncertain.
  • Evaluating periprocedural safety of percutaneous coronary intervention (PCI) versus coronary artery bypass grafting (CABG) for CTO in LVSD patients is crucial.

Purpose of the Study:

  • To compare the 30-day safety outcomes of CTO PCI and CTO CABG in patients with LVSD.
  • To identify predictors of major adverse cardiac or cerebrovascular events (MACCE) after CTO revascularization in this population.

Main Methods:

  • Retrospective analysis of patients with coronary heart disease, LVSD, and CTO undergoing PCI or CABG (2014-2020).
  • Primary endpoint: 30-day MACCE (all-cause mortality, cardiovascular mortality, stroke, MI, target vessel revascularization).
  • Inverse probability of treatment weighting (IPTW) and Cox regression were used for analysis.

Main Results:

  • 658 patients included: 440 (66.87%) underwent CTO PCI, 218 (33.13%) underwent CTO CABG.
  • 30-day MACCE occurred in 4.56% of patients, primarily due to all-cause mortality.
  • After IPTW adjustment, CTO CABG was associated with significantly higher risks of 30-day MACCE and MI compared to CTO PCI (P < 0.05).

Conclusions:

  • CTO CABG is linked to an increased risk of 30-day MACCE in patients with CTO and LVSD.
  • CTO PCI may offer superior postprocedural safety for these complex, high-risk patients.

Related Concept Videos

Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Acute Coronary Syndrome V: Nursing Management01:26

Acute Coronary Syndrome V: Nursing Management

Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...